All authors
Claude Skills by dromlakhani
github.com/dromlakhani875 skills0 installs1,377 views
- Eso Pediatric Obesity Hdl InterpretationInterprets HDL cholesterol levels to screen for dyslipidemia in pediatric patients using thresholds of <40 mg/dL low, 40–45 mg/dL borderline low, and ≥45 mg/dL acceptable. Triggered during lipid panel review for overweight or obese children (BMI ≥85th percentile) or when evaluating for cardiometabolic risk.Votes: 0GitHub stars: 12
- Eso Pediatric Obesity Healthy EatingPrescribes specific healthy eating habits for pediatric obesity prevention and treatment, focusing on avoiding calorie-dense nutrient-poor foods and encouraging whole fruits over juice. Trigger phrases include well-child visit, BMI ≥85th percentile, excessive juice intake, frequent fast food or sugary beverage consumption.Votes: 0GitHub stars: 12
- Eso Pediatric Obesity Infant DiagnosisDiagnoses obesity in infants and toddlers under 2 years of age when sex-specific weight-for-recumbent length is at or above the 97.7th percentile on WHO growth charts. Consider this assessment during well-child visits when caregivers report excessive weight gain, crossing of percentile channels, or when length and weight measurements suggest disproportionate adiposity.Votes: 0GitHub stars: 12
- Eso Pediatric Obesity Ldl InterpretationInterprets LDL cholesterol levels to screen for dyslipidemia in children and adolescents with obesity (BMI ≥85th percentile). Acceptable <110 mg/dL, borderline high 110-129 mg/dL, high ≥130 mg/dL triggers further evaluation or lifestyle intervention.Votes: 0GitHub stars: 12
- Eso Pediatric Obesity Non Hdl InterpretationWe need to output a SKILL.md file with the specified format.Votes: 0GitHub stars: 12
- Eso Pediatric Obesity Ogtt Glucose InterpretationInterprets the 2-hour plasma glucose from an oral glucose tolerance test (OGTT) to screen for prediabetes and diabetes in children and adolescents with overweight or obesity. Uses thresholds of <140 mg/dL (normal), 140–199 mg/dL (impaired glucose tolerance, IGT), and ≥200 mg/dL (diabetes) per ADA criteria referenced in the guideline.Votes: 0GitHub stars: 12
- Eso Pediatric Obesity Pcos Hormone InterpretationInterprets free and total testosterone and SHBG levels to screen for hyperandrogenism in adolescents with obesity, using Endocrine Society PCOS guidelines. Trigger phrases include oligomenorrhea, hirsutism, acne, and elevated androgen symptoms prompting PCOS evaluation.Votes: 0GitHub stars: 12
- Eso Pediatric Obesity Pharmacotherapy AdminDetermines when to administer FDA-approved obesity pharmacotherapy in pediatric patients, requiring a concomitant lifestyle modification program of the highest intensity and prescribing only by experienced clinicians. Triggers include documented failure of intensive lifestyle modification to limit weight gain or ameliorate comorbidities in patients with obesity (BMI ≥95th percentile).Votes: 0GitHub stars: 12
- Eso Pediatric Obesity Pharmacotherapy DiscontinueDetermines when to discontinue obesity pharmacotherapy due to lack of efficacy. Trigger phrases include “<4% BMI/BMI z score reduction after 12 weeks at full dosage” or “insufficient weight loss on antiobesity medication.”Votes: 0GitHub stars: 12
- Eso Pediatric Obesity Pharmacotherapy InitiateDetermines when to initiate pharmacotherapy for pediatric obesity after a formal intensive lifestyle modification program fails to limit weight gain or ameliorate comorbidities. Trigger phrases include "failed intensive lifestyle modification," "no weight loss despite lifestyle program," and "persistent comorbidities despite lifestyle intervention."Votes: 0GitHub stars: 12
- Eso Pediatric Obesity Physical ActivityPrescribes physical activity for pediatric obesity prevention and treatment in children and adolescents with BMI at or above the 85th percentile. Recommends at least 20 minutes, optimally 60 minutes, of vigorous physical activity on ≥5 days per week to improve metabolic health and reduce obesity risk.Votes: 0GitHub stars: 12
- Eso Pediatric Obesity Psychosocial EvalThis skill guides clinicians to evaluate for psychosocial comorbidities in pediatric obesity and to initiate assessment/counseling when psychosocial problems are suspected. Trigger phrases include family dysfunction, stressors, bullying, low self-esteem, depression, anxiety, eating disorders, or substance abuse.Votes: 0GitHub stars: 12
- Eso Pediatric Obesity Rearing PatternsThis skill guides clinicians to identify maladaptive rearing patterns related to diet, activity, and screen time in pediatric patients with overweight or obesity. It prompts evaluation of screen time, dietary habits, physical activity, and family eating cues to target education on healthy food and exercise habits.Votes: 0GitHub stars: 12
- Eso Pediatric Obesity Screen TimeRecommends limiting non-academic screen time to 1-2 hours per day and decreasing other sedentary behaviors. Trigger phrases include "excessive screen time," "digital activities," and "sedentary behaviors."Votes: 0GitHub stars: 12
- Eso Pediatric Obesity Total Cholesterol InterpretationThis skill interprets fasting total cholesterol levels to screen for dyslipidemia in children and adolescents undergoing obesity evaluation. Triggered by pediatric obesity screening (BMI ≥85th percentile) or dyslipidemia evaluation, it classifies cholesterol as acceptable (<170 mg/dL), borderline high (170‑199 mg/dL), or high (≥200 mg/dL) per Endocrine Society guidelines.Votes: 0GitHub stars: 12
- Eso Pediatric Obesity Triglycerides 0 9 YearsInterprets fasting triglyceride levels to screen for dyslipidemia in children aged 0–9 years during obesity evaluation. Triggered by BMI ≥85th percentile, well-child visit, or concern for metabolic comorbidity.Votes: 0GitHub stars: 12
- Eso Pediatric Obesity Triglycerides 10 19 YearsInterprets fasting triglyceride levels to screen for dyslipidemia in overweight or obese children aged 10-19 years. Triggered by pediatric obesity screening, fasting lipid panel, or BMI ≥85th percentile with clinical concern for dyslipidemia.Votes: 0GitHub stars: 12
- Monogenic Obesity DiagnosisDiagnose monogenic and syndromic obesity in children and adolescents using a structured step-by-step algorithm. Use this skill whenever a clinician suspects a genetic cause of obesity, asks about leptin deficiency, MC4R mutation, POMC deficiency, PCSK1 deficiency, leptin receptor deficiency, Bardet-Biedl syndrome, Prader-Willi syndrome, Alström syndrome, or any case of early-onset severe obesity with hyperphagia. Also trigger for questions about targeted pharmacotherapy including setmelanotid...Votes: 0GitHub stars: 12
- Pediatric Obesity ConsultationGuide a non-stigmatising pediatric obesity consultation using the 5As framework (Ask, Assess, Advise, Agree, Assist) and 4Ms assessment (Metabolic, Mechanical, Mental Health, Social Milieu), based on the CMAJ 2025 guideline. Trigger when a clinician asks how to approach a weight conversation with a child or family, how to use the 5As for obesity, how to assess a child with obesity, or how to conduct a non-judgmental obesity visit.Votes: 0GitHub stars: 12
- Pediatric Obesity Etiology ScreenerScreen a child with obesity for red flags suggesting monogenic, syndromic, or secondary endocrine causes — distinguishing atypical from typical exogenous obesity. Trigger when a clinician asks whether obesity could be genetic or hormonal, suspects Prader-Willi syndrome, Cushing disease, hypothyroidism, ROHHAD, Bardet-Biedl syndrome, leptin deficiency, or craniopharyngioma, or when a child has early-onset severe obesity, short stature with obesity, hyperphagia, hypotonia, dysmorphic features, ...Votes: 0GitHub stars: 12
- Pediatric Obesity Intervention SelectorSelect the right treatment tier for a child with obesity — behavioural, pharmacologic, or surgical — using the CMAJ 2025 pediatric obesity guideline. Trigger when a clinician asks what to do for a child with obesity, which intervention to start, whether to escalate treatment, or when to consider medication or surgery for pediatric obesity.Votes: 0GitHub stars: 12
- Pediatric Obesity Pharmacotherapy SelectorSelect the right pharmacologic agent for a child aged 12+ with obesity using the CMAJ 2025 guideline — choosing between GLP-1 receptor agonists, metformin, or orlistat with monitoring guidance. Trigger when a clinician asks which medication to use for pediatric obesity, whether to start semaglutide or metformin in a child, or how to manage obesity pharmacologically in adolescents.Votes: 0GitHub stars: 12
- Pediatric Obesity Surgical ScreenerScreen a child aged 13+ with obesity for eligibility for bariatric surgery (laparoscopic sleeve gastrectomy or Roux-en-Y gastric bypass) using the CMAJ 2025 guideline. Trigger when a clinician asks whether a child qualifies for weight loss surgery, bariatric surgery in adolescents, sleeve gastrectomy in a teenager, or when to refer for surgical management of pediatric obesity.Votes: 0GitHub stars: 12
- Ata Non Catecholamine Ppgl Diagnostic WorkupOrders mandatory MRI, contrast CT, and somatostatin receptor nuclear imaging when a non-catecholamine-producing pheochromocytoma or paraganglioma is suspected based on imaging findings with normal fractionated metanephrines and catecholamines. Considers SDHD germline genetic testing in hereditary head/neck paraganglioma cases triggered by multifocal or familial head/neck lesions.Votes: 0GitHub stars: 12
- Ata Pediatric Ppgl ApproachInvestigates for pheochromocytoma and paraganglioma in children presenting with hypertension plus symptoms such as headache, excessive sweating, or palpitations. Notes the absence of pediatric reference values for endocrine tests and selects tumor resection as first-line treatment when triggered by pediatric hypertension with associated symptoms like headache or excessive sweating.Votes: 0GitHub stars: 12
- Ata Ppgl Avoid Fna HnpglRecommends against fine needle cytology for pathological diagnosis of head and neck paraganglioma due to its low accuracy and risk of misdiagnosis. Use when a clinician asks 'Should I perform fine needle cytology for suspected head and neck paraganglioma?' — triggers include suspicion of head and neck paraganglioma requiring pathological confirmation.Votes: 0GitHub stars: 12
- Ata Ppgl Biomarker Use For PrognosisThis skill guides the use of biomarkers to prognosticate metastatic pheochromocytoma and paraganglioma (PPGL) by applying independent prognostic factors such as older age, larger tumor size, metastases at diagnosis, multiple metastases, high chromogranin A, plasma fractionated metanephrines ≥5× ULN, or elevated plasma 3‑MT; for head‑and‑neck PPGL, only high blood 3‑MT predicts disease‑specific survival. It is triggered when a clinician asks about prognosis based on biomarker results or encoun...Votes: 0GitHub stars: 12
- Ata Ppgl Bone Metastasis ManagementThis skill guides management of bone metastases in pheochromocytoma and paraganglioma, recommending external radiation therapy and surgical approaches similar to other solid cancers. It is triggered by known or suspected bone metastases, spinal cord compression symptoms, bone pain, pathological fracture, or hypercalcemia in a PPGL patient, emphasizing prompt diagnosis/treatment for spinal cord compression and consideration of bone-modifying agents for skeletal-related event prevention.Votes: 0GitHub stars: 12
- Ata Ppgl Chemotherapy IndicationRecommends CVD chemotherapy as first-line systemic treatment for unresectable pheochromocytoma/paraganglioma with rapid progression or when radionuclide therapy is not applicable. Considers disease progression rate and feasibility to choose between CVD chemotherapy and radionuclide therapy in patients with positive nuclear imaging when progression is slow and radionuclide therapy feasible.Votes: 0GitHub stars: 12
- Ata Ppgl Confirmatory Test SelectionSelects the appropriate confirmatory test after a positive pheochromocytoma/paraganglioma (PPGL) screening test. Triggers include elevated random urinary metanephrines (>3× ULN after creatinine correction), blood catecholamines (>3× ULN), or plasma-free fractionated metanephrines (>ULN).Votes: 0GitHub stars: 12
- Ata Ppgl External Beam Radiation IndicationRecommends stereotactic radiotherapy for local control of head and neck paraganglioma and postoperative radiotherapy for incompletely resectable spinal paraganglioma; considers external beam radiation therapy for local control of pheochromocytoma and paraganglioma outside the head and neck. Indicated when a clinician asks whether to recommend radiation therapy for local control in a PPGL patient, triggered by unresectable or incompletely resected PPGL lesion.Votes: 0GitHub stars: 12
- Ata Ppgl Genetic Marker Interpretation For MetsThis skill interprets SDHx and fumarate hydratase gene variants to assess metastasis risk in pheochromocytoma and paraganglioma patients. Triggered by identification of SDHB pathogenic variant (or negative SDHB immunostaining), FH variant, or other SDHx mutations when a clinician asks how genetic results affect metastasis risk assessment.Votes: 0GitHub stars: 12
- Ata Ppgl Genetic Testing IndicationIndicates and performs genetic testing for pheochromocytoma and paraganglioma when a clinician questions whether to order testing for a PPGL patient, using triggers such as any PPGL diagnosis, family history of PPGL, young age at onset (<50 years), bilateral adrenal tumors, or extra-adrenal (paraganglioma) location. It guides collection of detailed family and medical history, considers SDHB testing for high metastatic risk (35–75%), informs patients about hereditary PPGL significance, and rec...Votes: 0GitHub stars: 12
- Ata Ppgl Genetic Variant Treatment AlgorithmThis skill selects a treatment algorithm for pheochromocytoma and paraganglioma based on identified germline pathogenic variants, enabling personalized management per syndrome-specific guidelines. It is triggered when a clinician identifies RET, VHL, NF1, or SDHx pathogenic variants and asks how genetic results should change management.Votes: 0GitHub stars: 12
- Ata Ppgl Gi Symptom ManagementManages gastrointestinal symptoms from catecholamine excess in pheochromocytoma and paraganglioma, addressing constipation, paralytic ileus, megacolon, or intestinal pseudo-obstruction/perforation. Triggered by clinician queries about treating GI symptoms in PPGL patients with constipation, abdominal distension, or nausea/vomiting.Votes: 0GitHub stars: 12
- Ata Ppgl Histopathological ConfirmationThis skill confirms pheochromocytoma and paraganglioma (PPGL) diagnosis on histopathology by requiring immunostaining positive for Chromogranin A and negative for cytokeratin in tumor tissue, with SDHB negativity indicating SDHx pathogenic variants that predict metastasis or recurrence. It is triggered when a clinician asks 'How do I confirm pheochromocytoma diagnosis on pathology?' or encounters resected adrenal or paraganglioma tissue needing a definitive diagnosis.Votes: 0GitHub stars: 12
- Ata Ppgl Histopathological Scoring For MetsApplies histopathological scoring systems (GAPP, COPPS, PASS) to estimate metastasis risk in pheochromocytoma and paraganglioma. Used when a clinician asks 'What is the metastasis risk based on this pheochromocytoma pathology report?' and triggered by availability of histopathological specimen from PPGL resection.Votes: 0GitHub stars: 12
- Ata Ppgl Hypertensive Crisis ManagementAdministers intravenous phentolamine followed by infusion, then transitions to oral doxazosin after the acute phase resolves, while avoiding β-blockers before α-blockade. Indicated for severe hypertension (>180/110 mmHg) with headache, palpitations, or diaphoresis in known or suspected pheochromocytoma or paraganglioma.Votes: 0GitHub stars: 12
- Ata Ppgl Imaging Modality SelectionSelects the initial imaging modality (CT, MRI, 123I-MIBG scintigraphy, or 18F-FDG PET) for suspected pheochromocytoma and paraganglioma based on clinical question (tumor localization vs metastasis detection) and patient factors. Triggered by biochemical confirmation of PPGL or strong clinical suspicion when clinicians ask 'What imaging test should I order for suspected pheochromocytoma?'Votes: 0GitHub stars: 12
- Ata Ppgl Medical Treatment InitiationInitiates and adjusts medical treatment for functional pheochromocytoma and paraganglioma. Starts with selective α-blocker for catecholamine excess hypertension or symptoms, adds calcium antagonists or metyrosine if BP control insufficient, and adds β-blockers only after adequate α-blockade for tachycardia/tachyarrhythmia, myocardial damage, heart failure, or ischemic heart disease.Votes: 0GitHub stars: 12
- Ata Ppgl Metastasis Risk AssessmentAssesses metastasis risk in pheochromocytoma and paraganglioma using age at diagnosis, tumor size, catecholamine secretion pattern, timing of metastatic lesion diagnosis, tumor localization, disease type, histopathological findings, SDHB gene pathogenic variants, and SDHB immunohistochemistry status. Use when a clinician asks 'What is the metastasis risk for this pheochromocytoma patient?' Triggers include new PPGL diagnosis or change in clinical status during follow-up.Votes: 0GitHub stars: 12
- Ata Ppgl Pain Management PrecautionsCoordinates multidisciplinary treatment with palliative care unit for pain management while avoiding medications that risk inducing hypertensive crisis (e.g., metoclopramide, certain antidepressants) in PPGL patients. Triggered by reports of pain in PPGL patient, especially with bone involvement.Votes: 0GitHub stars: 12
- Ata Ppgl Perioperative Volume ManagementManages perioperative volume for pheochromocytoma and paraganglioma by initiating a normal salt diet (9 g/day) on day 3 of α‑blocker therapy, titrating intake to blood pressure and orthostatic changes, and administering 1–2 L saline pre‑operatively. Triggered when planning fluid/salt management for scheduled PPGL resection.Votes: 0GitHub stars: 12
- Ata Ppgl Preoperative Assessment Unclear OverproductionDetermines that α-blockers are generally unnecessary when catecholamine overproduction is unclear in suspected pheochromocytoma or paraganglioma, but requires comprehensive assessment of clinical findings before prescribing α-blockers before surgery. Use when a clinician asks 'Should I prescribe α-blockers preoperatively for this patient with suspected but unconfirmed pheochromocytoma?' Triggers include uncertain biochemical evidence of PPGL despite clinical suspicion.Votes: 0GitHub stars: 12
- Ata Ppgl Radionuclide Therapy SelectionThe skill selects 131I-MIBG therapy for pheochromocytoma or paraganglioma with positive 123I-MIBG scintigraphy that reduces excess catecholamines, or 177Lu-DOTATATE therapy for lesions with positive somatostatin receptor scintigraphy, both modalities covered by Japanese health insurance. It is invoked when a clinician asks which radionuclide therapy to use for metastatic or unresectable PPGL amenable to targeted treatment.Votes: 0GitHub stars: 12
- Ata Ppgl Screening Test SelectionChooses the initial screening test for suspected pheochromocytoma and paraganglioma when evaluating hypertension with paroxysmal symptoms, adrenal incidentaloma, or family history of PPGL. Selects among random urinary fractionated metanephrines (creatinine corrected), blood fractionated catecholamines, or plasma-free fractionated metanephrines.Votes: 0GitHub stars: 12
- Ata Ppgl Surgical Approach SelectionSelects surgical approach for pheochromocytoma and paraganglioma resection based on tumor size, invasion suspicion, metastatic status, and familial bilateral risk when a clinician asks 'What surgical approach should I use for this pheochromocytoma patient?' Triggers include confirmed PPGL requiring surgical intervention.Votes: 0GitHub stars: 12
- Ata Ppgl Surveillance Intensity DeterminationThis skill determines postoperative surveillance intensity for pheochromocytoma and paraganglioma based on hereditary status, catecholamine phenotype, tumor size, and location. Use when a clinician asks 'How long and how often should I follow up this pheochromocytoma patient after surgery?' with triggers such as completed PPGL resection, hereditary PPGL, sporadic PPGL with noradrenaline dominance, tumor diameter ≥5 cm, or extra-adrenal location outside head/neck.Votes: 0GitHub stars: 12
- Ata Ppgl Thyroid Block For MibgThe skill recommends administering potassium iodide (50–150 mg/day) or Lugol's solution (5–10 drops/day) for three days prior to and continuing through the day of 123I-MIBG scintigraphy to reduce thyroid radiation exposure and prevent medullary thyroid cancer in patients undergoing evaluation for pheochromocytoma or paraganglioma. It is triggered when a clinician questions whether to give a thyroid blocking agent for a 123I-MIBG scan, such as when ordering 123I-MIBG scintigraphy for PPGL eval...Votes: 0GitHub stars: 12
- Ata Pregnant Ppgl ManagementManage pheochromocytoma and paraganglioma in pregnancy by preferring ultrasound or MRI for imaging (avoiding CT/123I-MIBG unless benefits outweigh radiation risks), using selective α-blockers as first-line medical therapy (adding calcium antagonists if needed before delivery), and recommending tumor resection in the second trimester up to 24 weeks gestation when feasible. Triggers include pregnancy with hypertension, headaches, palpitations, or adrenal mass, and the clinician question “How sh...Votes: 0GitHub stars: 12